1.

Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Onc...

2.

Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Onc...

3.

Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Onc...

4.

Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Onc...

5.

Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Onc...

6.

Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Onc...

7.

Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Onc...

1.

Fewer pre-emptive renal transplantations and more rejections in immigrant children compared to native Dutch and Belgian children.

2.

Fewer pre-emptive renal transplantations and more rejections in immigrant children compared to native Dutch and Belgian children.

3.

Fewer pre-emptive renal transplantations and more rejections in immigrant children compared to native Dutch and Belgian children.

4.

Fewer pre-emptive renal transplantations and more rejections in immigrant children compared to native Dutch and Belgian children.

5.

Fewer pre-emptive renal transplantations and more rejections in immigrant children compared to native Dutch and Belgian children.

6.

Fewer pre-emptive renal transplantations and more rejections in immigrant children compared to native Dutch and Belgian children.

7.

Fewer pre-emptive renal transplantations and more rejections in immigrant children compared to native Dutch and Belgian children.

8.

Fewer pre-emptive renal transplantations and more rejections in immigrant children compared to native Dutch and Belgian children.

9.

Fewer pre-emptive renal transplantations and more rejections in immigrant children compared to native Dutch and Belgian children.

1.

Cost-effectiveness and screening performance of ECG handheld machine in a population screening programme: The Belgian Heart Rhythm Week screening programme.

2.

Cost-effectiveness and screening performance of ECG handheld machine in a population screening programme: The Belgian Heart Rhythm Week screening programme.

3.

Cost-effectiveness and screening performance of ECG handheld machine in a population screening programme: The Belgian Heart Rhythm Week screening programme.

4.

Cost-effectiveness and screening performance of ECG handheld machine in a population screening programme: The Belgian Heart Rhythm Week screening programme.

5.

Cost-effectiveness and screening performance of ECG handheld machine in a population screening programme: The Belgian Heart Rhythm Week screening programme.

6.

Cost-effectiveness and screening performance of ECG handheld machine in a population screening programme: The Belgian Heart Rhythm Week screening programme.

7.

Cost-effectiveness and screening performance of ECG handheld machine in a population screening programme: The Belgian Heart Rhythm Week screening programme.

8.

Cost-effectiveness and screening performance of ECG handheld machine in a population screening programme: The Belgian Heart Rhythm Week screening programme.

9.

Cost-effectiveness and screening performance of ECG handheld machine in a population screening programme: The Belgian Heart Rhythm Week screening programme.

1.

The belgian experience in unrelated donor bone marrow transplantation: identification of center experience as an important prognostic factor.

2.

The belgian experience in unrelated donor bone marrow transplantation: identification of center experience as an important prognostic factor.

3.

The belgian experience in unrelated donor bone marrow transplantation: identification of center experience as an important prognostic factor.

4.

The belgian experience in unrelated donor bone marrow transplantation: identification of center experience as an important prognostic factor.

5.

The belgian experience in unrelated donor bone marrow transplantation: identification of center experience as an important prognostic factor.

6.

The belgian experience in unrelated donor bone marrow transplantation: identification of center experience as an important prognostic factor.

7.

The belgian experience in unrelated donor bone marrow transplantation: identification of center experience as an important prognostic factor.

8.

The belgian experience in unrelated donor bone marrow transplantation: identification of center experience as an important prognostic factor.

9.

The belgian experience in unrelated donor bone marrow transplantation: identification of center experience as an important prognostic factor.

1.

Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients.

2.

Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients.

3.

Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients.

4.

Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients.

5.

Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients.

6.

Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients.

7.

Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients.

8.

Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients.

9.

Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients.

1.

Varicella paediatric hospitalisations in Belgium: a 1-year national survey.

2.

Varicella paediatric hospitalisations in Belgium: a 1-year national survey.

3.

Varicella paediatric hospitalisations in Belgium: a 1-year national survey.

4.

Varicella paediatric hospitalisations in Belgium: a 1-year national survey.

5.

Varicella paediatric hospitalisations in Belgium: a 1-year national survey.

6.

Varicella paediatric hospitalisations in Belgium: a 1-year national survey.

7.

Varicella paediatric hospitalisations in Belgium: a 1-year national survey.

8.

Varicella paediatric hospitalisations in Belgium: a 1-year national survey.

9.

Varicella paediatric hospitalisations in Belgium: a 1-year national survey.

1.

Burden of illness in patients with chronic hypoparathyroidism not adequately controlled with conventional therapy: a Belgium and the Netherlands survey.

2.

Burden of illness in patients with chronic hypoparathyroidism not adequately controlled with conventional therapy: a Belgium and the Netherlands survey.

3.

Burden of illness in patients with chronic hypoparathyroidism not adequately controlled with conventional therapy: a Belgium and the Netherlands survey.

4.

Burden of illness in patients with chronic hypoparathyroidism not adequately controlled with conventional therapy: a Belgium and the Netherlands survey.

5.

Burden of illness in patients with chronic hypoparathyroidism not adequately controlled with conventional therapy: a Belgium and the Netherlands survey.

6.

Burden of illness in patients with chronic hypoparathyroidism not adequately controlled with conventional therapy: a Belgium and the Netherlands survey.

7.

Burden of illness in patients with chronic hypoparathyroidism not adequately controlled with conventional therapy: a Belgium and the Netherlands survey.

8.

Burden of illness in patients with chronic hypoparathyroidism not adequately controlled with conventional therapy: a Belgium and the Netherlands survey.

9.

Burden of illness in patients with chronic hypoparathyroidism not adequately controlled with conventional therapy: a Belgium and the Netherlands survey.

1.

SPICT as a predictive tool for risk of 1-year health degradation and death in older patients admitted to the emergency department: a bicentric cohort study in Belgium.

2.

SPICT as a predictive tool for risk of 1-year health degradation and death in older patients admitted to the emergency department: a bicentric cohort study in Belgium.

3.

SPICT as a predictive tool for risk of 1-year health degradation and death in older patients admitted to the emergency department: a bicentric cohort study in Belgium.

4.

SPICT as a predictive tool for risk of 1-year health degradation and death in older patients admitted to the emergency department: a bicentric cohort study in Belgium.

5.

SPICT as a predictive tool for risk of 1-year health degradation and death in older patients admitted to the emergency department: a bicentric cohort study in Belgium.

6.

SPICT as a predictive tool for risk of 1-year health degradation and death in older patients admitted to the emergency department: a bicentric cohort study in Belgium.

7.

SPICT as a predictive tool for risk of 1-year health degradation and death in older patients admitted to the emergency department: a bicentric cohort study in Belgium.

8.

SPICT as a predictive tool for risk of 1-year health degradation and death in older patients admitted to the emergency department: a bicentric cohort study in Belgium.

9.

SPICT as a predictive tool for risk of 1-year health degradation and death in older patients admitted to the emergency department: a bicentric cohort study in Belgium.

1.

Prognostic Accuracy of Sepsis-3 Criteria for In-Hospital Mortality Among Patients With Suspected Infection Presenting to the Emergency Department.

2.

Prognostic Accuracy of Sepsis-3 Criteria for In-Hospital Mortality Among Patients With Suspected Infection Presenting to the Emergency Department.

3.

Prognostic Accuracy of Sepsis-3 Criteria for In-Hospital Mortality Among Patients With Suspected Infection Presenting to the Emergency Department.

4.

Prognostic Accuracy of Sepsis-3 Criteria for In-Hospital Mortality Among Patients With Suspected Infection Presenting to the Emergency Department.

5.

Prognostic Accuracy of Sepsis-3 Criteria for In-Hospital Mortality Among Patients With Suspected Infection Presenting to the Emergency Department.

6.

Prognostic Accuracy of Sepsis-3 Criteria for In-Hospital Mortality Among Patients With Suspected Infection Presenting to the Emergency Department.

7.

Prognostic Accuracy of Sepsis-3 Criteria for In-Hospital Mortality Among Patients With Suspected Infection Presenting to the Emergency Department.

1.

Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis.

2.

Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis.

3.

Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis.

4.

Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis.

5.

Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis.

6.

Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis.

7.

Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis.